Par Drugs and Chemicals Limited
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals
What Par files
- Others59
- Important29
- Board Meeting27
- Dividend/Bonus2
- Results1
- Updates1
Par Drugs And Chemicals Limited announced its 27th Annual General Meeting will be held in Vadodara. The Annual Report is available via web-link and distributed electronically to shareholders with registered emails.
The Board approved significant remuneration increases for key executives: MD & CEO to ₹0.64 Cr each, and an Independent Director to ₹0.24 Cr annually, pending shareholder vote. Directors were also empowered to lead company investment strategy, including appointing portfolio managers.
Par Drugs & Chemicals reports Q1 revenue of ₹31.28 Cr and profit of ₹4.71 Cr. The board approved new banking facilities with ICICI Bank and appointed NEO Alternative Asset Managers as Portfolio Manager, indicating proactive financial management.
Company's Board approved solid Q4/FY financial results: ₹107.66 Cr revenue & ₹13.11 Cr profit. Strong operating cash flow at ₹16.43 Cr. Greenlit ₹90 Cr for liquid fund investments and renewed a ₹1.61 Cr banking facility. Strategic restructuring faces regulatory delays, yet auditors affirm going concern.
Company approved financial results for the quarter and year with an unmodified auditor's opinion, despite regulatory restraint on a planned business restructuring. The Board approved new investments up to ₹90 Cr and renewed a banking facility of ₹1.61 Cr.